Entrada Therapeutics (TRDA) Q2 2024 Earnings
TRDA·Reported August 13, 2024·Before market open
Entrada Therapeutics reported Q2 2024 revenue of $94.7M, beat analyst consensus of $12.3M by $82.4M. Diluted EPS came in at $1.55, beat the $0.14 consensus by $1.41.
Revenue
$94.7Mbeat by $82.4M
Consensus: $12.3MDiluted EPS
$1.55beat by $1.41
Consensus: $0.14
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Entrada Therapeutics's Q2 2024 earnings report.
Entrada Therapeutics (TRDA) reported Q2 2024 earnings on August 13, 2024 before market open.
Entrada Therapeutics reported revenue of $94.7M and diluted EPS of $1.55 for Q2 2024.
Revenue beat the consensus estimate of $12.3M by $82.4M. EPS beat the consensus estimate of $0.14 by $1.41.
You can read the 10-Q periodic report (0001689375-24-000047) directly on SEC EDGAR. The filing index links above go to sec.gov.